Loading provider…
Loading provider…
Medical Oncology Physician in Duarte, CA
NPI: 1265480412Primary Employer
City of Hope - Upland
cityofhope.org
HQ Phone
Get M.D. Afsaneh's Phone NumberMobile
Get M.D. Afsaneh's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2011 - 2027
NV State Medical License
2023 - 2025
AK State Medical License
2022 - 2024
RI State Medical License
2021 - 2024
OH State Medical License
2008 - 2011
TX State Medical License
2005 - 2008
TX State Medical License
CA State Medical License

American Board of Internal Medicine
Medical Oncology
Cleveland Clinic Foundation
Fellowship • Hematology and Medical Oncology
2008 - 2011
University of Texas Medical Branch Hospitals
Residency • Internal Medicine
2001 - 2004
Tehran University of Medical Sciences School of Medicine
Medical School
Until 1996
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 44 | 139 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 33 | 54 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 13 | 20 |
| 5 | 99442Physician telephone patient service, 11-20 minutes of medical discussion | 13 | 19 |
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
Authors: Joleen Hubbard, Heinz-Josef Lenz, Fairooz Kabbinavar, Jason Starr, Timothy Cannon, Daniel Ahn
Publication Date: 2024-10-30
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI), Ipsen
Intervention / Treatment: OTHER: Questionnaire Administration, OTHER: Quality-of-Life Assessment, DRUG: Liposomal Irinotecan, BIOLOGICAL: Ramucirumab
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Pembrolizumab, DRUG: Regorafenib
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Serial Liquid Biopsy, PROCEDURE: Specimen Collection